{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:12Z","timestamp":1786979832964,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100021016","name":"Istituto di Ricovero e Cura a Carattere Scientifico","doi-asserted-by":"publisher","award":["101157011"],"award-info":[{"award-number":["101157011"]}],"id":[{"id":"10.13039\/100021016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtha.2025.08.020","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T23:28:35Z","timestamp":1757114915000},"page":"3845-3857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor\u2013platelet interaction"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-6011","authenticated-orcid":false,"given":"Paola","family":"Colpani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-6005","authenticated-orcid":false,"given":"Luciano","family":"Baronciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5059-5212","authenticated-orcid":false,"given":"Ilaria","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-9935","authenticated-orcid":false,"given":"Cristina","family":"Novembrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-4473","authenticated-orcid":false,"given":"Anna","family":"Lecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-3773","authenticated-orcid":false,"given":"Giovanna","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Boscolo","family":"Anzoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"La Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1917-5535","authenticated-orcid":false,"given":"Marco","family":"Boscarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-2271","authenticated-orcid":false,"given":"Maria Teresa","family":"Pagliari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0625-8320","authenticated-orcid":false,"given":"Andrea","family":"Artoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.08.020_bib1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.020_bib2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.020_bib3","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.020_bib4","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.020_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17512433.2019.1607293","article-title":"Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura","volume":"12","author":"Sargentini-Maier","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.08.020_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.020_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thromboticthrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.020_bib9","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/jth.15363","article-title":"Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab","volume":"19","author":"Schofield","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)","volume":"82","author":"Coppo","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jtha.2025.08.020_bib11","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with iTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.020_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","volume":"13","author":"Bod\u00f3","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2025.08.020_bib13","first-page":"619","article-title":"Evaluation of the different platelet-dependent von Willebrand factor activity assays capacity to assess the in vivo inhibitory effect of caplacizumab on the VWF-platelet interaction [abstract]","volume":"5","author":"Colpani","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11239-021-02492-6","article-title":"Monitoring the therapeutic effect of caplacizumab by von Willebrand Factor activity assays: proceed with caution","volume":"52","author":"Yates","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.08.020_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.18080","article-title":"Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab","volume":"197","author":"Bowyer","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.08.020_bib16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2014-05-378638","article-title":"von Willebrand factor, Jedi knight of the bloodstream","volume":"124","author":"Springer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.020_bib17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/09537104.2018.1535704","article-title":"Evaluation of the total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis","volume":"30","author":"Al Ghaithi","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2025.08.020_bib18","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.3390\/ijms22168605","article-title":"The use of Total thrombus formation analysis system as a tool to assess plateletfunction in bleeding and thrombosis risk a systematic review","volume":"22","author":"Sikora","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2025.08.020_bib19","first-page":"55","article-title":"Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects","volume":"22","author":"Lecchi","year":"2024","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2025.08.020_bib20","first-page":"77","article-title":"A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels","volume":"89","author":"Federici","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.08.020_bib21","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/jth.13062","article-title":"Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination","volume":"13","author":"Stufano","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V64.3.614.614","article-title":"Studies of the pathophysiology of acquired von Willebrand\u2019s disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies","volume":"64","author":"Mannucci","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.020_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/rth2.12141","article-title":"Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers","volume":"2","author":"Bowyer","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/jth.14319","article-title":"Clinically relevant differences between assays for von Willebrand factor activity","volume":"16","author":"Boender","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib25","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.jtha.2023.07.027","article-title":"Five years of caplacizumab lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura","volume":"21","author":"V\u00f6lker","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib26","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/j.1538-7836.2011.04428.x","article-title":"Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission","volume":"9","author":"Lotta","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.020_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2021.06.030","article-title":"High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP","volume":"567","author":"Lee","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtha.2025.08.020_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.020_bib29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.08.020_bib30","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2024-210866","article-title":"Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (TTP) mediated by VWF A1 domain missense mutation [abstract]","volume":"144","author":"Thomas","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.020_bib31","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1073\/pnas.0402041101","article-title":"Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13","volume":"101","author":"Nishio","year":"2004","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:39:41Z","timestamp":1773157181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625005458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1538783625005458"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor\u2013platelet interaction","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}